Estimating the burden of mpox among MSM in South Africa - McCabe, Ruth; Johnson, Leigh F.; Whittles, Lilith (medRxiv, 2024)
Despite seeing few cases during the 2022-23 mpox global outbreak, recent reports of 22 cases among men-who-have-sex-with-men (MSM) in South Africa, including three deaths, have raised concerns about underreported community transmission. We used a Monte Carlo simulation model to estimate the true epidemic size, considering increased severity of mpox among MSM living with advanced HIV (MSMLAHIV), documented overrepresentation of people living with HIV (PLHIV) among mpox cases, and HIV prevalence in South Africa. We estimate there have been between 220-450 cases among MSM LHIV in South Africa, implying a total of 290-560 cases among all MSM. We provide an upper bound of 750-1,600 cases as a sensitivity analysis where the prevalence of HIV among mpox patients is the same as population prevalence among MSM in South Africa. Estimates in both scenarios suggest a substantial number of undetected cases, with case ascertainment rates estimated between 1% and 8%. Our findings underscore the need for enhanced surveillance, targeted public health interventions, and awareness campaigns to mitigate the outbreak’s impact at a population-level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLKW acknowledges funding from the Wellcome Trust (grant number 218669/Z/19/Z). RM and LKW acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global Health EDCTP3 Joint Undertaking supported by the EU. The views expressed are those of the authors and not necessarily those of MRC or Wellcome.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used are publicly available case data published by the MoH in South Africa and WHO.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnalyses were performed in R v4.2.2; model code is available at https://github.com/mrc-ide/mpox_sa. All data are publicly available and cited in the manuscript.